Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Glioblastoma 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Liver Cirrhosis 1Gliosarcoma 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Cisplatin 68Paclitaxel 32Radiotherapy 31Carboplatin 23Bevacizumab 21pembrolizumab 20Brachytherapy 18atezolizumab 11camrelizumab 10Nivolumab 10Gemcitabine 10Drug Therapy 9tislelizumab 8Topotecan 8Taxes 8Chemoradiotherapy 8Radiation 7Docetaxel 7Albumin-Bound Paclitaxel 7zimberelimab 6toripalimab 6nimotuzumab 6Magnetic Resonance Spectroscopy 6Cetuximab 6lenvatinib 5durvalumab 5dostarlimab 5Platinum 5Papillomavirus Vaccines 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uterine Cervical Neoplasms × fluoromisonidazole × Clear all
NCT00559377 2016-12-30

FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 7 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡